RxDoctor Payments Data

Andrew Kelley, PA

Physician Assistant · Kingwood, TXNPI 1356930325

Payments from drug & device makers

$6,355in general payments, 2019–2025

Across 339 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$739
  • AstraZeneca$727
  • Novo Nordisk$614
  • Lilly USA, LLC$528
  • GSK$393
  • Boehringer Ingelheim$387
  • plus $3K from 23 others

What the payments were for

  • Food & beverage$6,354100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,355 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$4,386
Medicare patients
49
Services billed
350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$80,810
FarxigaDapagliflozin Propanediol30$30,852
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$25,891
JanuviaSitagliptin Phosphate21$16,581
EliquisApixaban14$12,849
Janumet XrSitagliptin Phos/Metformin Hcl13$9,326
Albuterol Sulfate HfaAlbuterol Sulfate111$2,781
Rosuvastatin Calcium142$2,648
Amlodipine-Valsartan-HctzAmlodipine/Valsartan/Hcthiazid12$2,545
Atorvastatin Calcium217$2,352
Gabapentin130$2,269
Olmesartan Medoxomil25$2,261
Losartan Potassium124$1,481
Levothyroxine Sodium173$1,384
Azelastine Hcl41$1,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$614$80,81071 claims
AstraZenecaFarxiga$727$30,85230 claims
MerckJanuvia, Janumet Xr$232$25,90734 claims
GSKTrelegy Ellipta$393$25,89136 claims
PfizerEliquis$29$12,84914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Kingwood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →